Unfavorable risk factors in early-stage HL per cooperative groups
| GHSG . | EORTC/LYSA . | NCCN . |
|---|---|---|
| Bulky mediastinal mass MMR >0.33 | Bulky mediastinal mass MTR >0.35 | Bulky mediastinal mass MMR >0.33 |
| Extranodal site | Presence of B symptoms | Adenopathy 10 cm in size or more |
| Nodal sites >2 | Nodal sites >3 | Nodal sites >3 |
| ESR >50 (or >30 if B symptoms) | ESR >50 (or >30 if B symptoms) | ESR ≥50 or any B symptoms |
| Age >50 |
| GHSG . | EORTC/LYSA . | NCCN . |
|---|---|---|
| Bulky mediastinal mass MMR >0.33 | Bulky mediastinal mass MTR >0.35 | Bulky mediastinal mass MMR >0.33 |
| Extranodal site | Presence of B symptoms | Adenopathy 10 cm in size or more |
| Nodal sites >2 | Nodal sites >3 | Nodal sites >3 |
| ESR >50 (or >30 if B symptoms) | ESR >50 (or >30 if B symptoms) | ESR ≥50 or any B symptoms |
| Age >50 |
EORTC, European Organization for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; GHSG, German Hodgkin Study Group; LYSA, Lymphoma Study Association; MMR, mediastinal mass ratio, maximum width of mass/maximum intrathoracic diameter; MTR, mediastinal thoracic ratio, maximum width of mediastinal mass/intrathoracic diameter at T5-6; NCCN, National Comprehensive Cancer Network.